Abstract
Aggregation of platelets using three antithrombotic agents such as Ticagrelor Derivative (TD-101), Rivaroxaban Analog (RA-202) and Apixaban Variant (AV-303) were assessed. All the three agents showed dose-dependent inhibitory effects in platelet aggregation where AV-303 exhibited the strongest inhibitory activity according to light transmission aggregometry. The statistical analysis showed distinctions (p < 0.05) between groups receiving treatment and controls. This opens possibilities for medical applications in thrombotic disorder treatment. It should be noted that additional animal tests and clinical studies are needed to validate effectiveness and safety of these agents.